Human Research Protection Office (HRPO)

Medicine & Life Sciences

1. Acute Myeloid Leukemia 100%
2. Lymphoma, Large B-Cell, Diffuse 97%
3. Cell Transplantation 96%
4. Allogeneic Cells 82%
5. plerixafor octahydrochloride 81%
6. Transplants 67%
7. Decitabine 65%
8. Hodgkin Disease 59%
9. Mantle-Cell Lymphoma 57%
10. Stem Cell Transplantation 54%
11. GATA2 Deficiency 51%
12. Survival 50%
13. Rituximab 49%
14. Hematopoietic Stem Cell Mobilization 48%
15. Lenalidomide 44%
16. Granulocyte Colony-Stimulating Factor 41%
17. Myelodysplastic Syndromes 40%
18. Lymphoma 40%
19. Stem Cells 40%
20. Tissue Donors 38%
21. Progression-Free Survival 38%
22. Natural Killer Cells 38%
23. Drug Therapy 38%
24. Follicular Lymphoma 38%
25. Azacitidine 37%
26. Recurrence 36%
27. Autologous Transplantation 36%
28. Cytarabine 36%
29. Therapeutics 35%
30. Interleukin-15 29%
31. belinostat 29%
32. Bendamustine Hydrochloride 28%
33. Confidence Intervals 28%
34. Chimeric Antigen Receptors 27%
35. Hematopoietic Stem Cell Transplantation 26%
36. Peripheral Blood Stem Cells 25%
37. Leukemia 24%
38. Peripheral T-Cell Lymphoma 23%
39. ALT-803 22%
40. Bone Marrow 22%
41. PCI 32765 22%
42. Non-Hodgkin's Lymphoma 21%
43. Homologous Transplantation 21%
44. Hematopoietic Stem Cells 21%
45. T-Lymphocytes 21%
46. Cell- and Tissue-Based Therapy 21%
47. Graft vs Host Disease 20%
48. B-Cell Lymphoma 19%
49. B-Cell Chronic Lymphocytic Leukemia 19%
50. Neoplasms 19%
51. Cyclophosphamide 19%
52. Transplantation 19%
53. Clofarabine 18%
54. Memory 16%
55. Mortality 16%
56. Mutation 15%
57. B-Lymphocytes 15%
58. T-Cell Lymphoma 14%
59. Unrelated Donors 14%
60. Cytomegalovirus 14%
61. fludarabine 14%
62. Multiple Myeloma 14%
63. Vincristine 13%
64. Maximum Tolerated Dose 13%
65. Standard of Care 13%
66. Clinical Trials 12%
67. Prednisone 12%
68. Histone Deacetylase Inhibitors 12%
69. Multicenter Studies 11%
70. Cytogenetics 11%
71. Veterans 11%
72. Allografts 11%
73. Tumor Burden 11%
74. IPI-145 10%
75. Safety 10%
76. axicabtagene ciloleucel 10%
77. Salvage Therapy 10%
78. AIC246 10%
79. Brentuximab Vedotin 10%
80. Doxorubicin 10%
81. Neutropenia 9%
82. Blood Component Removal 9%
83. Bortezomib 9%
84. Pharmacokinetics 9%
85. Lymphocytes 9%
86. Germinal Center 9%
87. ofatumumab 9%
88. Elderly 9%
89. midostaurin 9%
90. idelalisib 9%
91. Fluorodeoxyglucose F18 9%
92. Cytokines 9%
93. Bexarotene 8%
94. Gemtuzumab 8%
95. Melphalan 8%
96. Leukostasis 8%
97. Albumin-Bound Paclitaxel 8%
98. Filgrastim 8%
99. Appointments and Schedules 8%
100. Valganciclovir 8%